New drug duo tested in fight against stubborn blood cancers
NCT ID NCT04640779
Summary
This early-phase trial is testing the safety and best dose of a two-drug combination (selinexor and choline salicylate) for adults with advanced blood cancers that have returned or stopped responding to standard treatments. The study includes patients with non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, or related rare cancers. The main goal is to find the highest dose patients can tolerate without severe side effects while also checking if the treatment helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.